News & Insights

The unprecedented success of the COVID-19 vaccines, both therapeutically and commercially, has prompted fierce competition. Multiple companies around the world are fighting to claim patent rights related to these vaccines.

As the New York Times recently reported, ten years have passed since the first publication of a ground-breaking paper about the potential usefulness of CRISPR, “the gene-editing technology [that] has led to innovations in medicine, evolution and agriculture — and raised profound ethical questions about altering human DNA.”